Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
April 14, 2022 08:34 ET
|
Agios Pharmaceuticals, Inc.
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – –...
Agios to Participate in March Investor Conferences
February 28, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First...
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
February 17, 2022 15:41 ET
|
Agios Pharmaceuticals, Inc.
– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status – – Company to Provide Robust Patient Access...
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
February 10, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
January 10, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February – – Five Pivotal Clinical Trials are Planned and Ongoing in...
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
December 22, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
December 13, 2021 18:15 ET
|
Agios Pharmaceuticals, Inc.
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients – –...
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
December 13, 2021 10:30 ET
|
Agios Pharmaceuticals, Inc.
– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated – – Agios to Host Investor Webcast on Dec. 14,...
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
December 13, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients – – Safety Profile Consistent with Previously Reported Clinical Data – – Agios Announces Initiation of...